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Expression of the Epstein–Barr virus (EBV) immediate-early protein, BZLF1 (Z), is sufficient to disrupt viral latency. Z
transcriptionally activates the EBV early genes by binding to upstream Z-responsive elements (ZREs). Recently, a serine-to-
alanine mutation of Z residue 186 (within the basic DNA binding domain) was shown to inhibit the ability of Z to induce lytic
infection in latently infected cells, although the Z(S186A) mutant could still bind several known ZREs and activated an early
EBV promoter (BMRF1) in transient reporter gene assays (Francis, A. L., Gradoville, L., and Miller, G. (1997). J. Virol. 71,
3054–3061). We now show that a specific deficiency in the ability to bind to ZRE elements in the immediate-early BRLF1
promoter may account for the inability of Z(S186A) to activate BRLF1 expression. Furthermore, we demonstrate that the
ability of Z(S186A) to induce early BMRF1 and BHRF1 gene expression is rescued by cotransfection with a BRLF1 expression
vector. However, the Z(S186A)/BRLF1 (R) combination cannot induce full lytic replication, suggesting that Z(S186A) may also
be deficient in a replication-specific function. These results suggest that in the context of the intact viral genome, both Z and
R expression are required for activation of early gene transcription in latently infected cells. © 1998 Academic Press
INTRODUCTION
Epstein–Barr virus (EBV) is a human herpesvirus that
infects ;90% of the world’s population. EBV is the caus-
ative agent of infectious mononucleosis and has been
found to be associated with several forms of cancer,
including lymphomas and nasopharyngeal carcinoma
(Rickinson and Kieff, 1996; Zur Hausen et al., 1970). EBV
primarily infects two cell types, epithelial cells and B
cells (Rickinson and Kieff, 1996). In oral epithelial cells,
the virus readily replicates and exists in a lytic state
(Kieff, 1996; Li et al., 1992; Rickinson and Kieff, 1996;
Sixby et al., 1984). EBV infection of B cells usually results
in a latent type of infection (Kieff, 1996; Rickinson and
Kieff, 1996). However, in a small percentage of B cells,
the virus can become reactivated and replicate in a lytic
manner. This reactivation is initiated by expression of the
immediate-early genes, BZLF1 and BRLF1 (Chevallier-
Greco et al., 1986; Countryman and Miller, 1985; Kenney
et al., 1989b; Rooney et al., 1988; Rooney et al., 1989;
Takada et al., 1986; Zalani et al., 1996).
The BZLF1 (Z) and BRLF1 (R) proteins both have spe-
cific functional domains (Fig. 1) for transactivation, DNA
binding, and dimerization (protein–protein interactions)
(Cox et al., 1990; Flemington et al., 1992; Gruffat et al.,
1990A; Hardwick et al., 1992; Kouzarides et al., 1991;
Lieberman et al., 1989; Lieberman and Berk, 1990; Manet
et al., 1991; Packham et al., 1990; Quinlivan et al., 1993;
Urier et al., 1989). Z is a member of the bZIP family of
proteins and has homology within the DNA binding do-
main to the c-Fos and c-Jun proteins (Chang et al., 1990;
Farrell et al., 1989; Flemington and Speck, 1991). Z func-
tions as a transcriptional activator of other EBV early
gene promoters (Holley-Guthrie et al., 1990; Kenney et
al., 1989a; Lieberman et al., 1989; Quinlivan et al., 1993).
Z binds to Z-responsive elements (ZREs), which are
present in many of the EBV early gene promoters (Chang
et al., 1990; Farrell et al., 1989; Lieberman et al., 1989;
Quinlivan et al., 1993; Schepers et al., 1993), as well as in
the promoters of the two immediate-early genes (BRLF1
and BZLF1) (Flemington and Speck, 1990; Packham et al.,
1990). Z has also been shown to activate its own pro-
moter by a nonbinding, indirect mechanism (Flemington
et al., 1994), although it has not been shown whether this
type of activation is important in the context of the intact
viral genome. Z functions together with R to activate the
early EBV promoters (Cox et al., 1990; Giot et al., 1991;
Holley-Guthrie et al., 1990; Quinlivan et al., 1993). In B
cells, expression of Z, but not R, is sufficient to disrupt
latency, suggesting that during the disruption of viral
latency in B cells, Z is the initial viral gene expressed and
that Z subsequently activates R expression (Chevallier-
Greco et al., 1986; Countryman and Miller, 1985; Takada
et al., 1986; Zalani et al., 1996). In epithelial cells, how-
ever, expression of either Z or R is sufficient to disrupt
viral latency (Zalani et al., 1996). Z activity is also neces-
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sary for replication of the viral lytic origin of replication,
ori-Lyt (Fixman et al., 1992, 1995; Schepers et al., 1993).
Recently, an interesting EBV Z mutation has been de-
scribed (Francis et al., 1997) in which amino acid 186 is
changed from a serine to an alanine [Z(S186A); Fig. 1].
This mutation, located in the basic DNA binding region of
the protein, abolishes the protein’s ability to disrupt viral
latency, as measured by the inability of Z(S186A) to in-
duce expression of the EBV immediate-early BRLF1 or
early BMRF1 genes from the endogenous viral genome
(Francis et al., 1997). However, this mutated form of Z
retains its ability to bind to two known ZREs in the
BMRF1 promoter and was shown to transcriptionally
activate the BMRF1 promoter in reporter gene assays
(Francis et al., 1997).
In contrast to the previous report (Francis et al., 1997),
we now demonstrate that the Z(S186A) mutation changes
the binding specificity of the protein. Although Z(S186A)
binds efficiently to the ZRE sites in the BMRF1 promoter
(and activates this promoter in transient reporter gene
assays), it binds inefficiently to the ZRE sites in the
immediate-early BRLF1 promoter and does not activate
BRLF1 expression in latently infected cells. Furthermore,
we now demonstrate that the ability of Z(S186A) to acti-
vate BMRF1 expression in latently infected cells can be
rescued by cotransfection with the BRLF1 gene product.
Therefore, although Z alone is sufficient to activate many
early EBV promoters in transient reporter assays, both Z
and R expression are required for early EBV gene ex-
pression within the context of the intact viral genome.
RESULTS
Z(S186A) cannot bind to the ZREs of the R promoter
The BRLF1 promoter contains two ZREs that bind Z
(Packham et al., 1990), although the importance of these
sites in the disruption of viral latency has not been
established. Although it was previously shown (Francis
et al., 1997) that Z(S186A) can bind to the ZRE core motifs
present in the BRLF1 promoter, the previously reported
experiments used oligonucleotide probes not containing
the authentic BRLF1 promoter ZRE flanking sequences.
We performed an electromobility shift assay (EMSA) to
determine whether Z(S186A) binds efficiently to the two
BRLF1 ZRE sites containing genuine flanking sequences
(Fig. 2A). Although Z(S186A) bound as well as or better
than wild-type Z to the consensus AP1 and ZRE sites in
the BMRF1 promoter, and only slightly less efficiently
than wild-type Z to the ZRE sites in the EBV polymerase
promoter (Fig. 2B, lanes 10–12), Z(S186A) could not bind
efficiently to either ZRE in the BRLF1 promoter. In the
BZLF1 promoter, which contains two ZRE sites (ZIIIA and
ZIIIB), Z(S186A) bound to the ZIIIB site but did not bind to
the ZIIIA element (Fig. 2B). Therefore, Z(S186A) is defi-
cient in its binding to certain ZRE sites contained within
the BRLF1 and BZLF1 promoters.
The Z(S186A) mutation is a conversion of amino acid
186 from serine to alanine. Because serine 186 is a
possible target for phosphorylation, serine 186 may re-
quire phosphorylation (which could occur in reticulocyte
lysates) for Z to bind to the ZREs of the BRLF1 promoter.
To study the potential effect of Z phosphorylation, we
inserted the 186 mutation into a bacterial GST-Z fusion
protein. Fig. 3A shows that bacterially produced wild-
type Z and Z(S186A) behaved identically to the proteins
produced by in vitro translation in their relative binding
affinities. Because phosphorylation of Z is unlikely to
occur in bacteria, it does not appear that Z(S186A) phos-
phorylation is required for binding to the BRLF1 pro-
moter.
Z(S186A) cannot activate the R promoter in the
endogenous genome
BRLF1 expression may be necessary for the disrup-
tion of latency because the Z and R proteins cooperate
to activate certain EBV early gene promoters in some
transient reporter gene assay systems (Cox et al.,
FIG. 1. Functional domains of the R and Z proteins. The R and Z
domains for DNA binding (DNA), protein-protein dimerization (DIM),
and transactivation (TA) are presented. The Z(S186A) mutation is shown
below the Z protein.
FIG. 2. Z(S186A) cannot bind efficiently to the ZREs of the R promoter. (A) An EMSA was performed with 32P-labeled ZRE probes (RpZRE1 and
RpZRE2, from the R promoter; BMRF1-AP1 and BMRF1-ZRE, from the BMRF1 promoter) and in vitro translated Z and Z(S186A) proteins. Rabbit
reticulocyte lysate (retic.) was used as a control for each probe. An unlabeled AP1 competitor was used to specify the Z binding complexes (lanes
4 and 8). (B) An EMSA was performed with 32P-labeled ZRE probes (ZIIIA1B, from the Z promoter; PolZRE, from the EBV polymerase promoter) and
in vitro translated Z and Z(S186A) proteins. ZIII A2/B1 contains a mutant ZIIIA element and a wild-type ZIIIB element. ZIII A1/B2 contains a wild-type
ZIIIA element and a mutant ZIIIB element. (C) Equal amounts of in vitro translated Z and Z(S186A) proteins were used for all of the EMSAs. (D) The
sequences of each of the ZRE probes are presented. The core binding sequences are underlined. The ZIIIA1B oligo contains two ZRE sites, in
opposite orientations, and we have shown each separately.
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1990; Gruffat et al., 1990A; Holley-Guthrie et al., 1990).
Wild-type Z has been shown to activate BRLF1 expres-
sion from the endogenous genome (Kolman et al.,
1996; Le Roux et al., 1996; Zalani et al., 1996), but it is
not known whether Z binding to the BRLF1 promoter is
required for activation of BRLF1 in the context of the
intact viral genome. To examine the effect of Z(S186A)
on BRLF1 expression in latently infected cells, Raji or
D98/HE-R-1 cells were transfected with wild-type Z or
Z(S186A), and the level of BRLF1 expression was mon-
itored by immunoblot analysis. As shown in Fig. 4,
wild-type Z activated BRLF1 expression in both B cells
and epithelial cells, whereas Z(S186A) produced no
detectable BRLF1 expression in either cell type. Equal
amounts of Z and Z(S186A) proteins were produced
from the transfected plasmids as judged by immuno-
blot analysis with an anti-Z antibody (data not shown).
Similar to Z(S186A), the Z311 mutant could not activate
BRLF1 expression in latently infected cells (data not
shown). Thus Z-induced activation of BRLF1 from the
FIG. 3. Binding of bacterially produced Z and Z(S186A) proteins to the ZREs of the R promoter. (A) An EMSA was performed in an identical manner
to that in Fig. 2A, with 32P-labeled ZRE probes (RpZRE1 and RpZRE2, from the R promoter; BMRF1-AP1 and BMRF1-ZRE, from the BMRF1 promoter),
except that bacterially produced GST, GST-Z, and GST-Z(S186A) proteins were used. An unlabeled AP1 competitor was used to specify the Z binding
complexes (lanes 4 and 8). (B) Coomassie-stained gel showing the relative amounts of GST, GST-Z, and GST-Z(S186A) proteins used in the EMSA.
FIG. 4. Z(S186A) does not induce R protein expression. (A) Raji cells were transfected with a total of 10 mg of vector control DNA and/or the Z and
R expression vectors as shown. Immunoblot analysis was performed using a monoclonal antibody directed against the R protein [anti-R (1:10) from
Alain Sergeant]. (B) D98/HE-R1 cells were transfected with a total of 10 mg of vector control DNA or the Z and R expression vectors as shown, and
immunoblot analysis was performed as described in A.
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endogenous viral genome likely requires direct bind-
ing to the BRLF1 promoter.
The addition of BRLF1 (R) can bypass the Z(S186A)
mutation and lead to the expression of BMRF1
The inability of Z(S186A) to activate BRLF1 transcrip-
tion suggests that the addition of exogenous R might
rescue the ability of Z(S186A) to disrupt viral latency.
Therefore, we examined the ability of wild-type Z,
Z(S186A), and Z311, in the presence or absence of co-
transfected R, to induce early EBV gene expression in a
variety of latently infected cell types (Fig. 5). The expres-
sion of wild-type Z alone induced BMRF1 expression in B
cells (Raji), as expected. As previously shown, neither
the expression of Z(S186A) alone nor R alone in Raji cells
induced BMRF1 expression. However, the combination
of Z(S186A) plus R induced BMRF1 expression in Raji
cells as efficiently as wild-type Z. Thus the presence of R
is able to rescue the ability of Z(S186A) to activate
BMRF1 expression. Equivalent results were obtained us-
ing the latently infected EBV-positive B cell lines Jijoye
and B95–8 (data not shown). Similar results were also
obtained in the D98/HE-R-1 cell line (Fig. 5B), except that
in this cell type R alone induced a certain level of BMRF1
expression (as previously reported in Zalani et al., 1996).
Similar to Z(S186A), the Z311 mutant, which cannot bind
directly to DNA, did not activate BMRF1 expression in
either B cells or epithelial cells. However, in contrast to
Z(S186A), Z311 could not be rescued by the addition of R
(Fig. 5A). Therefore, direct Z binding to early EBV promot-
ers is likely required for their activation in the endoge-
nous genome.
Z(S186A) plus R can activate another early protein,
BHRF1
To test whether the combination of Z(S186A) plus R
can activate other early gene promoters in latently in-
fected cells, we performed immunofluorescence on
transfected cells, examining BHRF1 expression. As a
control, we also examined BMRF1-expressing cells from
the same transfection. As shown in Table 1, transfection
of Raji cells with wild-type Z induced a significantly
higher level of BHRF1 expression (6.4%) than the vector-
transfected cells (0.6%). Similarly, the combination of
Z(S186A) plus R-transfected cells had a significantly
higher level of BHRF1 expression (4.1%) than the vector-
transfected cells, whereas Z(S186A) or R alone had no
effect. Thus the Z(S186A)-plus-R combination activates a
variety of early EBV proteins in latently infected B cells.
Z(S186A) can transcriptionally activate several EBV
early and immediate-early promoters in transient
reporter gene assays
Although it is clear that Z(S186A) cannot activate the
BMRF1 promoter in the context of the intact viral ge-
nome, a previous study demonstrated that Z(S186A) ac-
tivates the BMRF1 promoter in transient reporter gene
assays (Francis et al., 1997). To extend this analysis, we
FIG. 5. The R protein can restore the ability of Z(S186A) to induce BMRF1 expression. (A) Raji cells were transfected with a total of 10 mg of either
vector control DNA and/or the various Z and R expression vectors as indicated. Immunoblot analysis was performed using a monoclonal antibody
directed against the BMRF1 protein [anti-EBV, EAD (1:40), from Capricorn]. (B) D98/HE-R1 cells were transfected with a total of 10 mg of either vector
control DNA or the various Z and R expression vectors as indicated, and immunoblot analysis was performed as described in A.
TABLE 1
BHRF1 and BMRF1 Expression in Transfected Raji Cells
Transfected
plasmid(s)
BHRF1 expression
(%)
BMRF1 expression
(%)
Vector 0.6 1.0
Z 6.4 15.6
Z(S186A) 0.3 0.7
R 0.7 1.0
Z(S186A) 1 R 4.1 21.3
Note. Raji cells were transfected with vector control DNA or the
various expression vectors as indicated. The percentage of cells pos-
itive for BHRF1 or BMRF1 expression was determined with BHRF1 or
BMRF1 antibody staining and FACS analysis.
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assessed the ability of Z(S186A) to activate a variety of
early EBV gene targets promoters (BHLF1, BHRF1, and
BMRF1) in transient reporter gene assays. As shown in
Fig. 6A, Z(S186A) significantly activated all three of these
early EBV promoters.
We next examined the effect of Z(S186A) versus wild-
type Z on the activity of the EBV immediate-early promot-
ers, BZLF1 and BRLF1, in transient reporter gene assays.
As shown in Fig. 6B, both the wild-type Z and Z(S186A)
significantly activated the BZLF1 promoter in transient
reporter gene assays (although the wild-type Z was more
efficient). Similarly, Z(S186A) activated the BRLF1 pro-
moter at least as efficiently as the wild-type Z in transient
reporter gene assays. However, because a mutant form
of Z (Z311), which is unable to bind directly to DNA, also
significantly activated (15- to 20-fold) the BRLF1 promoter
in these assays, we conclude that Z can activate both
EBV immediate-early promoters through indirect (non-
DNA binding) mechanisms in transient transfection as-
says. These results suggest (in contrast to the results
obtained in the intact viral genome) that Z-induced
activation of the BZLF1 and BRLF1 promoters in tran-
sient reporter gene assays does not require direct bind-
ing of Z.
Z(S186A) plus R cannot fully disrupt latency
To compare the ability of wild-type Z versus Z(S186A)
plus R to induce full lytic viral replication in latently
infected B cells, we performed Southern blot analysis to
distinguish latent (episomal) versus lytic (linear) EBV
genomes, as described previously (Sato et al., 1990). As
shown in Fig. 7, in Z-transfected Jijoye cells, the linear
form of the virus is induced, as expected. However,
FIG. 6. Z(S186A) can transactivate EBV early and immediate-early gene promoters in reporter gene assays. (A) DG75 cells were transfected with
5 mg of each promoter construct (BHLF1-CAT, BHRF1-CAT, or EApBS-CAT) and 5 mg of either vector control DNA, Z expression plasmid, or Z(S186A)
expression plasmid. CAT assays were performed as described. The average fold-activation, relative to vector alone, is presented. (B) DG75 cells were
transfected with 5 mg of reporter construct (ZpBS-CAT or RpBS-CAT) and 5 mg of either vector control DNA, Z expression plasmid, Z(S186A) expression
plasmid, or Z311 expression plasmid.
FIG. 7. The combination of Z(S186A) plus R cannot induce lytic viral
replication. Jijoye and DG75 cells were transfected with 10 mg of vector
control DNA or the Z and R expression vectors as indicated. The viral
DNA was isolated 72 h posttransfection, cut with BamHI, and analyzed
by Southern blot using a 32P-labeled riboprobe spanning the 1.9-kb XhoI
sequence of EBV. This assay distinguishes between latent virus (fused
termini only) and lytic virus (an increased number of fused termini plus
linear forms). The position of the replication linear intermediates is
indicated (* indicates the position of transfected plasmids also de-
tected by the probe).
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neither Z(S186A) alone nor Z(S186A) plus R-transfected
cells exhibited the replicative form of the virus, indicating
that the viral genome did not replicate in these cells. The
extra bands that are present in lanes 3–5 of Fig. 7
correspond to plasmid sequences that were also de-
tected by the probe and were observed in DG75 (EBV-
negative) cells transfected with Z.
To confirm the above result, we performed immunoflu-
orescence on transfected B95–8 cells, testing for viral
capsid antigen (VCA) expression. VCA is an EBV late
protein that is expressed only after all of the early pro-
teins have been expressed and the genome has been
lytically replicated. As shown in Table 2, B95–8 cells
transfected with wild-type Z had a significantly higher
level of VCA expression (14.1%) than the vector-trans-
fected cells (1.0%). However, neither Z(S186A) alone nor
the Z(S186A)-plus-R combination induced significantly
more VCA expression than the vector alone. Therefore,
the combination of Z(S186A) plus R, although sufficient to
activate at least two EBV early promoters (BMRF1 and
BHRF1), does not result in late protein expression and
cannot fully disrupt latency.
DISCUSSION
Expression of the EBV immediate-early protein Z acti-
vates the transcription of early EBV promoters and is
sufficient for disruption of EBV latency. Although the
other EBV immediate-early protein, R, can function syn-
ergistically with Z to activate certain EBV early promoters
in reporter gene assays (Cox et al., 1990; Holley-Guthrie
et al., 1990; Quinlivan et al., 1993), expression of BRLF1
alone is not sufficient to disrupt viral latency in B cell
lines (Zalani et al., 1996), and R is not absolutely essen-
tial for ori-Lyt replication in plasmid-based assays (Fix-
man et al., 1992, 1995). Therefore (in the absence of a
mutant virus missing the BRLF1 gene product), it has
remained uncertain whether BRLF1 expression is essen-
tial for Z-induced disruption of viral latency in B cells or
merely increases its efficiency.
In this report, we demonstrate that the Z(S186A) mu-
tant is impaired in its ability to bind (and activate) the
BRLF1 promoter from the endogenous viral genome in
latently infected cells. However, because the Z(S186A)
mutant retains its ability to bind (and activate) at least a
subset of EBV early promoters, the addition of R protein
to Z(S186A) restores the ability of this mutant to activate
expression of EBV early genes (e.g., BMRF1 and BHRF1)
from the endogenous viral genome. Therefore, in the
context of the intact viral genome, activation of the BRLF1
promoter is the first essential step in Z-mediated disrup-
tion of viral latency, and early EBV transcription clearly
requires both BZLF1 and BRLF1 expression.
The findings reported here indicate that the results
obtained using transient reporter gene assays do not
always accurately predict the effects (and mechanisms)
of the Z and R proteins in the context of the intact EBV
genome. For example, although both the Z(S186A) and
Z311 (neither of which bind directly to the BRLF1 pro-
moter) mutants can activate the BRLF1 promoter in tran-
sient reporter gene assays (through as-yet-undefined
indirect mechanisms), we show here that neither of
these mutants can activate BRLF1 expression from the
endogenous viral genome. Francis et al. (1997) have
likewise found that Z(S186A) does not induce BRLF1
transcription in Raji cells. Thus it is almost certain that
direct Z binding is required for activation of BRLF1 in the
intact virus (unless both the Z311 and Z(S186A) mutants
have serendipitously altered another function of BZLF1).
Although we (and others) have previously used re-
porter gene assays to predict that certain early EBV
promoters (including BMRF1 and BHRF1) are synergisti-
cally activated by the Z-plus-R combination (Cox et al.,
1990; Holley-Guthrie et al., 1990; Quinlivan et al., 1993),
this effect was very cell type dependent and was not
observed at all in certain epithelial cells (Gruffat et al.,
1990B; Holley-Guthrie et al., 1990; Quinlivan et al., 1993).
In contrast, in the context of the intact virus, Z(S186A)
activation of the early EBV promoters clearly requires the
R helper function in both B cells and epithelial cells.
Although the requirement for R during disruption of la-
tency in the intact genome may simply reflect its known
function as a transcriptional transactivator, it remains
possible that R has other essential roles in the intact
genome that are not measured in plasmid-based assays.
At least two R binding sites (in the BMLF1 and BHRF1
promoters) have been shown to have an R-dependent
enhancer function (Chevrier et al., 1989; Cox et al., 1990;
Gruffat et al., 1990a; Kenney et al., 1989A), suggesting
that R binding in the intact viral genome could potentially
alter DNA structure. For example, if the early promoters
in the latent EBV genome are normally tightly wound in
chromatin such that Z cannot easily bind to upstream
ZRE sites, R binding to early EBV enhancers might be
required to alter chromatin structure before Z binding
could occur. Alternatively, R could activate the function of
TABLE 2
VCA Expression in Transfected B95-8 Cells
Transfected plasmid(s) VCA expression (%)
Vector 1.0
Z 14.1
Z(S186A) 1.9
R 1.4
Z(S186A) 1 R 1.1
Note. B95-8 cells were transfected with vector control DNA or the
various expression vectors as indicated. The percentage of cells pos-
itive for VCA expression was determined with VCA antibody staining
and FACS analysis.
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cellular proteins required for Z-induced activation of
early gene promoters in the intact genome.
The Z(S186A) mutant cannot bind efficiently to either of
the BRLF1 ZRE sites in vitro, correlating with its inability
to activate BRLF1 expression in vivo. When comparing
the sequences of various ZRE sites in the BMRF1, BZLF1,
polymerase, and BRLF1 promoters (Fig. 2C), it is imme-
diately apparent that the Z(S186A) mutant is unable to
bind to either of the two ZRE sites (RpZRE1 and ZpZIIIA)
containing the core sequence TGAGCCA. The other site
not bound by Z(S186A), RpZRE2 (TGAGCGA), is the only
site that contains a G at the sixth nucleotide position.
Interestingly, however, Z(S186A) binds even more effi-
ciently than wild-type Z to the consensus AP1 binding
site (TGAGTCA). The basic DNA binding domain in the
Z(S186A) protein more closely resembles that of the
c-Jun and c-Fos proteins than wild-type Z, perhaps ex-
plaining why Z(S186A) binds even more efficiently than
wild-type Z to the consensus AP1 site, yet (like c-Jun and
C-Fos) cannot bind to at least some ZRE sites.
Although it has been speculated that the inability of
Z(S186A) to disrupt viral latency reflects the loss of serine
186 phosphorylation (Francis et al., 1997), it is clear from
our results (comparing bacterial and in vitro translated
proteins) that phosphorylation of serine 186 is not re-
quired for binding to the BRLF1 ZRE sites. Therefore, this
particular aspect of the in vivo Z(S186A) phenotype (the
inability to activate the BRLF1 promoter) is unlikely to
reflect decreased Z phosphorylation. It is possible that
wild-type Z can adopt more than one conformation and
that although one conformation favors binding to the
BRLF1 ZRE sites, another conformation favors binding to
early promoter ZREs. In this case, the Z(S186A) mutant
may have lost the ability to adopt the conformation that
binds to the BRLF1 ZREs. The ability of Z to assume
subtly different conformations in vivo could act to regu-
late its binding affinity for the different classes of pro-
moters (immediate-early versus early versus delayed-
early), thereby ensuring that Z initially activates the
BRLF1 immediate-early promoter and then preferentially
binds to early promoters when adequate levels of the R
protein have been synthesized.
Even though the combination of Z(S186A) plus R can
activate a variety of early genes from the endogenous
viral genome, Z(S186A) plus R does not induce full lytic
viral replication of the virus in B cells. It is possible that
this lack of lytic replication reflects the inability of
Z(S186A) to bind (and activate) an essential early repli-
cation gene promoter, similar to its inability to bind the
BRLF1 promoter. We have shown that Z(S186A) binds to
at least two of the six known essential replication pro-
teins (BMRF1 and polymerase) but have not tested the
promoters of the remaining four genes known to be
required for ori-Lyt replication (Fixman et al., 1992, 1995).
Alternatively, the Z(S186A) mutant may be specifically
defective in its replicative functions, as has been re-
ported for other Z mutants (Sarinsky et al., 1996). It
remains possible, for example, that phosphorylation of
serine 186, although not required for transcriptional ac-
tivation of early EBV promoters, is essential for ori-Lyt
replication.
The Z(S186A) mutant demonstrates that Z-induced ac-
tivation of BRLF1 is essential for disruption of viral la-
tency in B cells and should prove a useful tool for map-
ping the domains in transfected R protein required for
this function. The Z(S186A) mutation also demonstrates
that Z recognizes various ZRE sites through different
mechanisms, an aspect of Z binding that is potentially
exploited by the virus to regulate Z binding in a temporal
fashion.
MATERIALS AND METHODS
Cell lines
Raji and Jijoye are EBV-positive Burkitt’s lymphoma
cell lines. DG75 is an EBV-negative Burkitt’s lymphoma
cell line. B95–8 is a productively infected, EBV-positive,
marmoset B cell line. The epithelial D98/HE-R-1 cell line
was formed by fusion of a HeLa cell subclone (D98) with
the EBV-positive Burkitt’s lymphoma cell line P3HR/1
(Glaser and O’Neill, 1972). All lymphoid cell lines were
maintained in RPMI 1640 medium supplemented with
10% fetal calf serum. Epithelial cell lines were maintained
in Dulbecco’s modified Eagle’s medium H supplemented
with 10% fetal calf serum.
EBV plasmids
EApBS-CAT contains the early EBV BMRF1 promoter
sequences from 2331 to 11 linked to the chloramphen-
icol acetyltransferase (CAT) gene (Quinlivan et al., 1993).
BHRF1-CAT contains a 1020-bp NaeI–HincII fragment of
the early EBV BHRF1 promoter (EBV positions 52800–
53819) linked to the CAT gene (Gutsch et al., 1994).
BHLF1-CAT contains the early EBV BHLF1 promoter se-
quences from 21031 to 1165 linked to the CAT gene
(Zhang et al., 1996). ZpBS-CAT was constructed by re-
moving the BZLF1 promoter (sequences from 2552 to
112) linked to the CAT gene (an XbaI–BamHI fragment)
from Z-CAT (Kenney et al., 1989B) and inserting it into the
pBS vector. RpBS-CAT contains the immediate-early
BRLF1 promoter sequences from 2962 to 15 linked to
the CAT gene (Zalani et al., 1992).
The Z expression vector contains the BZLF1 gene
(genomic clone) downstream of the early SV40 promoter
(gift of Erik Flemington) (Flemington et al., 1992). The
Z(S186A) expression vector was derived from the afore-
mentioned Z expression vector but has a point mutation
that changes amino acid 186 (in the DNA binding do-
main) from serine to alanine (gift of Erik Flemington). The
R expression vector contains the BRLF1 genomic clone
downstream of the CMV immediate-early promoter in the
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pHD1013 vector (Holley-Guthrie et al., 1990). The Z311
expression vector contains a mutated form of the BZLF1
cDNA (in which amino acid 185 is altered from alanine to
lysine) downstream of the CMV immediate-early pro-
moter, in the pHD1013 vector (Giot et al., 1991; Kenney et
al., 1992). The Z311 mutation abolishes DNA binding
activity (Giot et al., 1991; Kenney et al., 1992).
The Z cDNA plasmid contains the BZLF1 cDNA in the
pSP64 vector (a gift from Paul Farrell) (Farrell et al., 1989).
The Z(S186A) cDNA plasmid contains the mutated BZLF1
cDNA (amino acid 186 altered from serine to alanine) in
the pBlueScript KS1 vector (gift of Erik Flemington).
pGEX-3X-Z(S186A) was constructed by swapping the 39
half of the Z(S186A) cDNA (an NheI–EcoRI fragment) with
the 39 half of the Z cDNA (an NheI–EcoRI fragment) in the
pGEX-3X-Z vector (Quinlivan et al., 1993).
DNA purification
Plasmid DNA was purified through QIAGEN columns
as described by the manufacturer (QIAGEN). Viral DNA
was purified as follows: cells were resuspended in 0.4 ml
of lysis buffer (10 mM Tris–HCl, pH 7.9, 10 mM EDTA,
0.6% SDS, 1 M sodium chloride), incubated for 20 min at
room temperature, and stored overnight at 4°C. The
extract was centrifuged for 30 min at 4°C. The superna-
tant (containing viral DNA and RNA) was incubated with
RNase for 2 h at 37°C. The pellet (containing protein,
SDS, and cellular DNA) was saved for protein analysis.
DNA transfection
DNA (5–10 mg) was transfected into cells by electro-
poration with a Zapper electroporation unit (Medical
Electronics Shop, University of Wisconsin) at 1500 V as
described previously (Tonneguzzo et al., 1986). All cells
were resuspended in RPMI 1640 medium before electro-
poration.
CAT assays
Cell extracts were prepared 48 h posttransfection and
incubated at 37°C with [14C]chloramphenical in the pres-
ence of acetyl coenzyme A as described previously (Gor-
man et al., 1982). The percent acetylation of chloram-
phenical was quantified by thin layer chromatography
followed by PhosphorImager screening (Molecular Dy-
namics).
Immunoblot analysis
Raji and D98/HE-R-1 cells were transfected with a total
of 10 mg of DNA. Immunoblot analysis was performed for
the detection of the EBV BMRF1 and BRLF1 proteins
follows: briefly, 30 mg of protein was loaded onto each
lane, and SDS–PAGE was performed. The proteins were
transferred overnight onto nitrocellulose (Protran),
blocked in 13 PBS/5% milk/0.1% Tween 20, and incu-
bated in primary antibody for 1 h at room temperature
[anti-EBV, EA-D (1:40), from Capricorn; anti-R (1:10), from
Alain Sergeant]. The membrane was washed in PBS/0.1%
Tween 20, incubated in secondary antibody for 1 h at
room temperature [goat anti-mouse k-horseradish per-
oxidase (GAM-k-HRP; 1:2000), from Southern Biotechnol-
ogy] and washed, and the results visualized with the ECL
chemiluminescent kit (Amersham) according to the man-
ufacturer’s instructions.
Z protein expression
The Z cDNA plasmid was linearized with EcoRI and
transcribed with SP6 polymerase, using the Riboprobe
System II kit from Promega. The resulting RNA was
translated in the presence of [35S]methionine using the
rabbit reticulocyte lysate system (Promega). The
Z(S186A) cDNA plasmid was linearized with SacI, tran-
scribed with T3 polymerase, and translated as for Z.
Protein quantities were normalized by running aliquots of
each protein on an SDS–polyacrylamide gel, followed by
autoradiography.
Glutathione-S-transferase (GST), GST-Z, and GST-
Z(S186A) proteins were induced, sonicated, and centri-
fuged. Protein quantities were normalized by affinity pu-
rifying aliquots of the proteins, followed by SDS–PAGE
and Coomassie staining. Crude protein was used for
EMSAs.
EMSAs
EMSAs were performed as described previously (Gar-
ner and Revzin, 1981). The synthetic double-stranded
oligonucleotides used in the binding reactions were 59-
end labeled with 32P using the Klenow reaction. RpZRE1
(59-GATCTCTTTTATGAGCCATTGGCA-39) spans 226 to
245, relative to the RNA start site, of the BRLF1 promoter
(Packham et al., 1990). RpZRE2 (59-GATCAAGCTTAT-
GAGCGATTTTAT-39) spans 2184 to 2203, relative to the
RNA start site, of the BRLF1 promoter (Packham et al.,
1990). AP1 (59-GATCGATGACCTTTGAGTCAGGTGGCTA-
39) spans 273 to 250, relative to the RNA start site, of
the BMRF1 promoter (Quinlivan et al., 1993). ZRE (59-
GATCTAATTTCTTTGAGCAAGAGAGTTCC-39) spans 2119
to 296, relative to the RNA start site, of the BMRF1
promoter (Quinlivan et al., 1993). PolZRE (59-GA-
TCGCGCTGCATGAGCAAAACCAGGAG-39) spans 248
to 225, relative to the RNA start site, of the EBV poly-
merase promoter (Furnari et al., 1992). ZIIIA1B
(59-GATCATGCATGAGCCACAGGCATTGCTAATGTA-
CCT-39) spans 2134 to 2103, relative to the RNA start
site, of the BZLF1 promoter (Flemington and Speck,
1990). ZIII A2/B1 (59-GATCATGCAGAATTCGCAGGCATT-
GCTAATGTACCT-39) contains a mutant ZIIIA site; ZIII
A1/B2 (59-GATCATGCATGAGCCACAGGCAGCAGCT-
GTGTACCT-39) contains a mutant ZIIIB site. The in vitro
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translated proteins and GST proteins were prepared as
described above.
The binding reactions were conducted in a buffer
consisting of 100 mM potassium chloride, 20 mM HEPES
(pH 7.3), 10% glycerol, 0.2 mM EDTA, 4 mM dithiothriotol,
and protease inhibitors with 4 mg of poly(dI-dC)/poly(dI-
dC) (Pharmacia). Five microliters of in vitro translated
protein or 5 mg of GST protein was added to each
reaction and incubated at room temperature for 10 min
before the addition of labeled probe (20,000 cpm). After
addition of the probe, the reactions were incubated 30
min at room temperature and then loaded onto a 4%
polyacrylamide gel and run in 0.53 Tris–borate–EDTA
(TBE) at room temperature.
EBV termini analysis
Jijoye and DG75 cells were transfected with 10 mg of
DNA. Viral DNA was prepared at 72 h posttransfection.
Twenty micrograms of DNA was cut with BamHI, run on
an 0.8% agarose gel, and transferred to Hybond-N. The
blot was probed with a 32P-UTP-labeled riboprobe span-
ning the EBV sequences in the 1.9-kb XhoI fragment (a
gift from Nancy Raab-Traub) (Sato et al., 1990).
Fluorescence activated cell sorter (FACS) analysis
B95–8 or Raji cells were transfected with 10 mg of
DNA. Cells were harvested 48–72 h posttransfection.
Cells were washed twice with PBS, fixed with 60% ace-
tone for 10 min on ice, washed three times in PBS–0.5%
bovine serum albumin (BSA), and incubated with the
primary antibody [VCA (1:10), from Virotech; BMRF1 (1:
30), from Capricorn; EA-R (1:50), from Chemicon] for 1 h
at room temperature. The cells were washed three times
and then incubated in the secondary antibody [GAM-
FITC (1:100), from Sigma] for 1 h at room temperature.
The cells were washed three times and resuspended in
0.5 ml of PBS. The percentage of immunofluorescent
cells was determined with a FACS machine (Becton-
Dickinson).
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